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Abstract
Microsomal prostaglandin E synthase-1 (mPGES-1) is an inducible
enzyme that catalyzes the conversion of prostaglandin (PG)H2 to
PGE2. Proinflammatory stimuli markedly increase levels of
mPGES-1 expression both in vivo and in vitro. mPGES-1 knockout
studies and animal models of inflammatory arthritis also provide a
strong basis for the contribution of mPGES-1 in the increased
local production of PGE2 observed in inflammatory arthritis. The
focus of this article is to review some recent advances in our
understanding of mechanisms specific to the regulation of
inducible mPGES-1 in inflammatory arthritis.
Introduction
Prostaglandin (PG)E2 is the pivotal eicosanoid involved in the
development and perpetuation of inflammation seen in
diseases such as rheumatoid arthritis. In this disease, local
inflammation of synovial tissue is characterized in part by
increased local levels of PG, predominantly PGE2 [1]. In the
eicosanoid pathway, induction of PGE2 biosynthesis during
inflammation requires the enzymatic actions of two cytokine-
inducible enzymes: cyclooxygenase (COX) and prostaglandin
E synthase (PGES) (Fig. 1). An important role for COX-2 in
producing PG in patients with inflammatory arthritis has been
clearly shown in clinical trials that demonstrate equal efficacy
of specific COX-2 inhibitors and nonspecific nonsteroidal anti-
inflammatory drugs (NSAIDs) [2]. Whether a similar essential
role exists for the inducible microsomal prostaglandin E
synthase-1 (mPGES-1) in the localized increase of PGE2
during inflammatory arthritis in humans is currently unclear.
Biology of mPGES-1
Microsomal prostaglandin E2 synthase-1 belongs to the
MAPEG (membrane-associated proteins involved in eicosanoid
and glutathione metabolism) superfamily (Table 1). It was
initially identified as a homologue to another member
(MGST1; see Table 1) and was found to have significant
glutathione-dependent PGE2 synthase activity [3]. The
human mPGES-1 gene maps to chromosome 9q34.3,
contains three exons and two introns, and spans approxi-
mately 14.8 kb [4]; the purified recombinant enzyme weighs
approximately 17.5 kDa. It has a Vmax of 170 µmol min–1 mg–1
and a kcat/Km of 310 mM–1 s–1 for the conversion of PGH2 to
PGE2 at 37°C, which is orders of magnitude higher than
other terminal PG synthases and establishes a key role for
mPGES-1 in PGE2 synthesis in vivo [5]. There is 80%
sequence homology between mouse/rat and human mPGES-
1. Mutation of Arg110, but not Tyr117, results in abrogation
of the catalytic function of mPGES-1 [6]; these two amino
acids are highly conserved in the MAPEG superfamily.
In addition to mPGES-1, two other isoforms of PGE synthase
have been cloned and characterized. Cytosolic PGES
(cPGES) is constitutively expressed in a wide variety of
mammalian cell lines and tissues and is not responsive to
stimulation with bacterial lipopolysaccharide (LPS) [7].
Another isoform, termed microsomal PGES-2 (mPGES-2), is
ubiquitously expressed under basal conditions in many
tissues and is activated by reducing agents [8]. The relative
roles of these constitutive enzymes for basal PGE2
production are currently unclear. Furthermore, it has not yet
been determined if these enzymes can contribute to
increased PGE2 production during inflammation. Of the two
enzymes, it appears that mPGES-2 can function more
effectively in conjunction with COX-2, while both cPGES and
mPGES-2 are capable of functioning efficiently with COX-1
to produce PGE2.
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Role of mPGES-1 in inflammation in vivo
In wild-type rats and mice, constitutive mPGES-1 expression
in tissues such as stomach and kidney appear to contribute
to small amounts of basal PGE2 production [9,10]. However,
upon injection with LPS, these animals show up-regulation of
mPGES-1 in most tissues and markedly increased PGE2
production [9-11].
In rat paws of acute (carrageenan-induced) and chronic
(adjuvant-induced) arthritis models, significant up-regulation
of mPGES-1 RNA and protein expression was observed,
compared with other PGE synthases, and was also
associated with elevated PGE2 levels [9,12,13]. Consistent
with these findings, increased mPGES-1 expression is seen
in synovial tissue of patients with rheumatoid arthritis [14,15].
Insight into the role of mPGES-1 in inflammatory disease has
been facilitated by the development of mPGES-1 null mice by
two different groups: one on a C57BL/6 × 129/SvJ back-
ground, the other on a DBA1/lacJ background [16,17]. Both
strains of mice exhibit normal longevity and fertility and are
phenotypically indistinguishable from their wild-type litter-
mates. In mPGES-1 knockout mice injected with LPS, PGE2
synthase activity was only minimally increased in tissues. In
peritoneal macrophages derived from LPS-stimulated mPGES-
1 knockout mice, minimal elevation in PGE2 production, but
no difference in tumor necrosis factor α (TNF-α), IL-6, or
IL-12 levels was observed [10,11,16,17]. Together, these
findings establish mPGES-1 as a critical source of inducible
PGE2 synthetic activity in vivo.
The importance of mPGES-1 in inflammatory arthritis was
further demonstrated by a study of collagen-induced arthritis
in mPGES-1 null mice. These mice exhibited reduced
incidence and severity of disease compared with wild-type
controls, both clinically and histopathologically. This
difference was not associated with alterations in IL-6
production by peritoneal macrophages or significant
differences in circulating IgG2a anticollagen antibodies [16].
In collagen-antibody-induced arthritis, mPGES-1 null mice
had a similar incidence but a lesser severity of arthritis than
wild-type mice, as well as a 50% reduction in paw levels of
PGE2 [11]. In other models of inflammation, mPGES-1 null
mice show impaired delayed-type hypersensitivity responses
[16], as well as some evidence for impaired formation of
inflammatory granulation tissue and angiogenesis [11].
Figure 1
The prostaglandin E2 (PGE2) biosynthetic pathway. DP, PGD2
receptor; EP, PGE2 receptor; FP, PGF2α receptor; mPGES,
microsomal prostaglandin E synthase; PG, prostaglandin; TP,
thromboxane A2 receptor; TXA2, thromboxane A2.
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Table 1
Members of the MAPEG protein superfamily
Protein Biological properties
Microsomal glutathione S-transferase 1 (MGST1) Glutathione S-transferase, glutathione peroxidase
MGST1-like1 (MGST1-L1) Glutathione-dependent PGE2 synthase activity
Microsomal glutathione S-transferase (MGST)-2, -3 Glutathione S-transferase, glutathione peroxidase
5-Lipoxygenase-activating protein (FLAP) Activation of leukotriene synthesis
Leukotriene C4 synthase (LTC4S) Glutathione S-transferase specific for LTA4
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The role of mPGES-1 in the central nervous system regulation
of fever and nociception in inflammatory states is also well
described. Animal pyresis models show transient up-regulation
of mPGES-1 mRNA in brain endothelial cells after systemic
injection with endotoxin or IL-1 [18,19]. Additionally, peripheral
inflammation from carageenan-injected paws was associated
with increased mPGES-1 expression and PGE2 levels in the
central nervous system [12]. In a more chronic inflammation
model, rats with adjuvant-induced arthritis displayed sustained
induction of mPGES-1 by immunohistochemistry in the brain
vasculature and the paraventricular nucleus of the
hypothalamus [20]. mPGES-1 null mice did not generate
fevers in response to peripheral LPS injection but did become
febrile after intracerebroventricular PGE2 injection [21].
Together, these findings highlight PGE2 derived from mPGES-
1 in the central nervous system as a critical mediator in
inflammation-induced pyresis.
Studies also describe mPGES-1 in pain models. mPGES-1
null mice exhibit diminished writhing in response to
intraperitoneal injections of acetic acid (especially after LPS
priming [11]), similar to NSAID-treated wild-type mice [16].
There was no difference between null and wild-type mice in
withdrawal latency upon thermal stimuli, a model of non-
inflammatory pain [16,22]. However, in a model of neuro-
pathic pain involving hyperalgesia following transection of an
L5 (fifth lumbar) spinal nerve, mPGES-1 null mice had higher
withdrawal thresholds and latency upon both mechanical and
thermal stimuli compared with wild-type mice [22].
Regulation of mPGES-1
Similar to COX-2, mPGES-1 is highly up-regulated by
proinflammatory stimuli and participates in the generation of
elevated PGE2 in inflammation. In response to IL-1β and/or
TNF-α, up-regulation of mPGES-1 expression is observed in
rheumatoid arthritis synovial fibroblasts, as well as in many
other cell types [6,23-26]. Moreover, an antisense oligo-
nucleotide blocking mPGES-1 expression inhibits PGE2
production, osteoclastogenesis, and bone resorption in
mouse osteoblast coculture stimulated with IL-1β and TNF-α
[26]. The inhibitory actions of glucocorticoids also establish
an important role for mPGES-1 in inflammation. In studies
examining rheumatoid arthritis synovial cells and osteoarthritis
chondrocytes, treatment with dexamethasone decreased
mPGES-1 mRNA and protein expression mediated by
proinflammatory cytokines [23,25,27].
To date, few studies have addressed signal transduction
mechanisms responsible for up-regulation of mPGES-1 in
arthritis. Masuko-Hongo and colleagues have recently
demonstrated a role for extracellular-signal-regulated kinase-
activated and p38β mitogen-activated protein kinase
signaling pathways in the regulation of mPGES-1 expression
in osteoarthritic chondrocytes stimulated with IL-1β [24].
However, further investigations are necessary to more
extensively define signaling mechanisms that influence the
modulation of induced mPGES-1 expression.
The promoter region of the mPGES-1 gene does not contain
transcriptional elements that are present in the COX-2
promoter and promoters of other cytokine-inducible genes [4]
(Fig. 2). Examination of a 651-bp promoter region revealed
the presence of GC boxes, Barbie boxes, and an aryl
hydrocarbon regulatory element (ARE), consistent with other
members of the MAPEG and glutathione-S-transferase
families. The mPGES-1 promoter lacks a TATA box and other
transcriptional elements typically identified in cytokine-
responsive genes. Using a promoter-reporter construct of
–651 to –20 bp, modest yet significant transcriptional
stimulation by IL-1β was observed in A549 cells [4]. The
differences in promoter structure and timing of induction
suggest that divergent transcriptional mechanisms are
responsible for the inducible regulation of COX-2 and
mPGES-1. It was recently shown that the zinc-finger-
containing transcription factor, early growth response gene-1
(Egr-1) binds specifically to GC-rich elements in the mPGES-
1 promoter region and facilitates murine mPGES-1 gene
transcription [28]. More recently, PPARγ ligands have been
shown to suppress Egr-1-mediated induction of the activities
of the mPGES-1 promoter, and a synthetic promoter-reporter
construct in IL-1β-stimulated osteoarthritic synovial fibro-
blasts [29]. Further analyses will be required to better define
Figure 2
Regulatory elements of the human microsomal prostaglandin E synthase-1 (mPGES-1) and cyclooxygenase-2 promoters. AP-1 or -2, activator
protein-1 or -2; c/EBP, CCAAT/enhancer-binding protein; GR, glucocorticoid receptor; NFκB, nuclear factor κB; PR, progesterone receptor; Sp1,
specificity protein-1.
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gene regulatory mechanisms that modulate the increased
expression of mPGES-1, as seen in inflammation.
Conclusions
Our understanding of PG biosynthetic pathways has
increased enormously over the past 20 years with the cloning
and characterization of a number of enzymes responsible for
generation of specific PG. This pathway has been a target for
therapeutic intervention in inflammation, pain, and fever for
centuries. However, drugs that interfere with the COX
enzymes, including COX-2-specific drugs, are associated
with significant adverse effects in the gastrointestinal, renal,
and cardiovascular systems. Continuing study of other
potential targets, including mPGES-1, may yield new
approaches to the treatment of symptoms mediated by
increased local production of prostaglandins.
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